Navigation Links
Increasing Use of Allergan's Botox and the Launch of Novel Nontriptan Products Will Be Key Drivers of Migraine Market Growth Through 2022
Date:12/3/2013

BURLINGTON, Mass., Dec. 3, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the use of Allergan's Botox for the prophylactic treatment of chronic migraine will increase modestly in the major pharmaceutical markets (United States, France, Germany, Italy, Spain, the United Kingdom and Japan) through 2022, despite lingering clinical and market access hurdles. The drug's expanding role, especially in the United States, coupled with its premium price, will propel its major-market sales for migraine to nearly $850 million in 2022. Greater use of Botox will help drive 4 percent annual growth of the total migraine market—which includes both episodic and chronic migraine—which Decision Resources forecasts will expand from nearly $3.6 billion in 2012 to $5.4 billion in 2022.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO)

The Pharmacor advisory service entitled Migraine finds that the expected launch of two premium-priced nontriptan therapies for the acute treatment of migraine, Allergan's Levadex and CoLucid Pharmaceuticals' 5-HT1F receptor agonist lasmiditan, will also fuel the migraine market growth through 2022. As therapeutic alternatives for triptan nonresponders, patients unable to tolerate triptans, or, in the case of lasmiditan, patients in whom triptans are contraindicated, these agents are expected to earn combined sales accounting for 25 percent of the total migraine market in 2022.

The findings also reveal that the
'/>"/>

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Increasing Incidence of Cardiovascular Diseases to Drive The Cardiovascular Devices Market in Emerging Countries
2. Pharma Execs Continue Looking For Growth Opportunities In Spite Of Increasing Regulatory Challenges: KPMG Survey
3. Diabetes Care Devices in Emerging Countries (China, India, Brazil) to 2017 - Greater Awareness is Increasing Demand for Self-Monitoring of Blood Glucose (SMBG) in the Home Care Segment
4. Cardiac Rhythm Management Devices Market to 2017 - Technological Innovations, Regulatory Approvals and Increasing Disease Prevalence Present Growth Opportunities
5. Patient Monitoring Devices Market to 2017 - Increasing Use of Wireless Remote Patient Monitoring to be the Key Technology Trend
6. Increasing Minimal Invasive Surgeries to Boost Adoption of Hybrid Operating Rooms in Europe, Says Frost & Sullivan
7. Social Norms, Life Changes and Increasing Pressures Contribute to Substance Abuse Among Adult Women
8. Patient Monitoring Devices Market in Emerging Countries (China, India, Brazil) to 2017 - Increasing Government Spending and Foreign Direct Investment (FDI) to Drive Future Growth
9. RMANJ Research Demonstrates That Egg Freezing Prior To IVF Yields Positive Outcomes Without Increasing Risk Of Aneuploidy
10. Global Hospital Supplies Market to 2018 - Increasing Preference for Electro-mechanical Tables over Conventional Hydraulic Models to Drive Market Growth: MarketResearchReports.Biz
11. AssureRx Health Expands Management Team to Support Increasing Business Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... 28, 2015 According to a ... (Breast, Lung, Prostate) Type (Protein & Genetic Biomarkers) Profiling ... Prognostic) & Geography - Global Forecast to 2020", published ... reach around 17,689.0 Million USD by 2020 at a ... to 2020. Browse 191 Tables and ...
(Date:8/28/2015)... 2015 Research and ... of the "12th Annual Report and Survey ... to their offering. The 2015 12th ... and Production is the most recent study of ... projected future capacity and production. The report contains ...
(Date:8/28/2015)... WARRENVILLE, Ill. , Aug. 28, 2015 /PRNewswire/ ... Patterson Companies, Inc. (Nasdaq: PDCO ), is ... the previously announced acquisition of Patterson Medical by ... Medical will retain its name for a transition ... distributor of rehabilitation and sports medicine products.  With ...
Breaking Medicine Technology:Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 2Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 3Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 4Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 512th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 3
... subset analyses of progression-free survival in,the SPARC ... in,relative risk of disease progression for patients ... as well as presence or absence of ... Pharmion,Corporation and GPC Biotech AG today announced ...
... Results in Improved Long-term [Five-years],Overall Survival for ... 2007 /PRNewswire-FirstCall/ -- FOLFOX4, an,Eloxatin(R)-based chemotherapy regimen, ... survival (OS) and,time to disease progression (TTP) ... in patients with metastatic (advanced) colorectal cancer.,Importantly, ...
Cached Medicine Technology:Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 2Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 3Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 4Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 5Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 6Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 7Eloxatin (oxaliplatin injection)-Based Chemotherapy Sets New,Treatment Benchmark in Patients With Metastatic Colorectal Cancer 2Eloxatin (oxaliplatin injection)-Based Chemotherapy Sets New,Treatment Benchmark in Patients With Metastatic Colorectal Cancer 3Eloxatin (oxaliplatin injection)-Based Chemotherapy Sets New,Treatment Benchmark in Patients With Metastatic Colorectal Cancer 4
(Date:8/28/2015)... ... ... An online provider of CPAP machines, masks, supplies, and accessories, My Cpap ... by offering shipping at no cost to you, directly to your door on all ... My Cpap Store is located in Las Vegas, Nevada. , Sleep apnea is a ...
(Date:8/28/2015)... ... 2015 , ... With the goal of furthering music education programs in schools, ... Adams County Fairgrounds in Mendon, IL on May 30th, 2015. Backed once again by ... in the underfunded school districts of Mendon and its neighboring town of Quincy, IL. ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... The ... the renowned Brain Aneurysm Foundation has added yet another accolade to its cadre of ... Emanuel. , “With the help of the medical community and the University ...
(Date:8/28/2015)... , ... August 28, 2015 , ... “ Frequentz ” ... at the latest and coolest applications on the market for iOS, Android, and Windows. ... shared with viewers how this software allows businesses to track product movement from beginning ...
(Date:8/28/2015)... ... 2015 , ... The Nashville Business Journal recently announced its ... Mr. Troy Mizell, Chairman of the Board at MyGenetx, is one of ... Awards will recognize Nashville military veterans who, through their professional and personal efforts, ...
Breaking Medicine News(10 mins):Health News:My Cpap Store Now Offering Delivery Special 0 Cost to You 2Health News:Best Drug Rehabilitation Interviews Country-Rock Duo Highway Run at the 2015 "Music With A Mission" Benefit Concert 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 3Health News:Track Product Movement from Beginning to End with Frequentz 2Health News:MyGenetx Board Member Receives Veterans Award 2
... the safety of a potential vaccine against mesothelioma, a ... which infuses uses a patient,s own dendritic cells (DC) ... induce a T-cell response against mesothelioma tumors. "[This] ... patients with mesothelioma," wrote Joachim G Aerts M.D., Ph.D., ...
... A new iPhone app designed ... gone on sale on the App Store , ... (PRWeb UK) March 3, 2010 -- The Quickka Calories PRO iPhone app is aimed at ... items that they eat., , ,In what is being called a perfect union between technology and ...
... ... ... ... ...
... ... , ... , , , ... HOUSTON , March ...
... University of Texas M. D. Anderson Cancer Center, researchers found ... bladder cancer, is a cost-effective method of detecting tumors. ... well as the number of false positives that may result ... The study was presented today in advance of the American ...
... University of Washington,s Dr. H. Hunter Handsfield, a long-time ... the nation,s highest honor in the STD field during ... STD Prevention Conference in Atlanta, March 8-11. Handsfield ... named for Dr. Thomas Parran, Jr., U.S. Surgeon General ...
Cached Medicine News:Health News:Possible vaccine for mesothelioma proven safe 2Health News:Barcode Joins the Battle of the Bulge in New iPhone App 2Health News:Osteotech to Present at the Canaccord Adams Musculoskeletal Conference 2Health News:Osteotech to Present at the Canaccord Adams Musculoskeletal Conference 3Health News:Omega Protein Comments on California Lawsuit Alleging Fish Oil Contaminants 2Health News:Costly tests may not help detect bladder cancer recurrence, M. D. Anderson study finds 2Health News:Dr. Hunter Handsfield wins prestigious Thomas Parran Award 2Health News:Dr. Hunter Handsfield wins prestigious Thomas Parran Award 3Health News:Dr. Hunter Handsfield wins prestigious Thomas Parran Award 4
... For use as a quality assurance ... human immunodeficiency virus type 1 (anti-HIV-1), ... I (anti-HTLV-I), antibody to hepatitis C ... core antigen (anti-HBc), antibody to cytomegalovirus ...
... the first,diagnostic hepatitis assay approved by the,U.S. ... in a random access format on,the VITROS ... run a hepatitis test at any time, ... for,the qualitative in vitro determination of total,antibody ...
... This SIGNET anti-PSA antibody gives ... all cases of benign hyperplasia. In ... intense staining and 34% give definite ... only a minority of cells; this ...
... kit is based on sequential binding of ... one (specific for the *-chain of HCG) ... (specific for the *-chain of HCG) conjugated ... washing step, chromogenic substrate is added and ...
Medicine Products: